Related Experiment Video
Updated: Mar 21, 2026

Author Spotlight: Epigenetic Modifications and Metabolic Rewiring as Targets for Cancer Therapy
Published on: October 18, 2024
Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of
Junjian Wang1, Zhijian Duan1, Zoann Nugent2
1Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, Sacramento, CA 95817, United States.
Abstract:
Metabolic reprogramming such as the aerobic glycolysis or Warburg effect is well recognized as a common feature of tumorigenesis. However, molecular mechanisms underlying metabolic alterations for tumor therapeutic resistance are poorly understood. Through gene expression profiling analysis we found that histone H3K36 methyltransferase NSD2/MMSET/WHSC1 expression was highly elevated in tamoxifen-resistant breast cancer cell lines and clinical tumors. IHC analysis indicated that NSD2 protein overexpression was associated with the disease recurrence and poor survival. Ectopic expression of NSD2 wild type, but not the methylase-defective mutant, drove endocrine resistance in multiple cell models and xenograft tumors. Mechanistically, NSD2 was recruited to and methylated H3K36me2 at the promoters of key glucose metabolic enzyme genes. Its overexpression coordinately up-regulated hexokinase 2 (HK2) and glucose-6-phosphate dehydrogenase (G6PD), two key enzymes of glycolysis and the pentose phosphate pathway (PPP), as well as TP53-induced glycolysis regulatory phosphatase TIGAR. Consequently, NSD2-driven tamoxifen-resistant cells and tumors displayed heightened PPP activity, elevated NADPH production, and reduced ROS level, without significantly altered glycolysis. These results illustrate a coordinated, epigenetic activation of key glucose metabolic enzymes in therapeutic resistance and nominate methyltransferase NSD2 as a potential therapeutic target for endocrine resistant breast cancer.
Insights
The histone methyltransferase NSD2 drives tamoxifen resistance in breast cancer by epigenetically upregulating glucose metabolism enzymes. This suggests NSD2 as a therapeutic target for endocrine-resistant breast cancer.
Area of Science:
- Oncology
- Epigenetics
- Cancer Metabolism
Background:
- Metabolic reprogramming, including the Warburg effect, is a hallmark of cancer.
- Molecular mechanisms of metabolic alterations contributing to therapeutic resistance remain unclear.
- Endocrine resistance is a significant challenge in breast cancer treatment.
Purpose of the Study:
- To investigate the molecular mechanisms underlying metabolic alterations in tamoxifen-resistant breast cancer.
- To identify potential therapeutic targets for endocrine-resistant breast cancer.
Main Methods:
- Gene expression profiling of tamoxifen-resistant breast cancer cell lines and tumors.
- Immunohistochemistry (IHC) to assess NSD2 protein levels.
- Functional studies involving ectopic expression of NSD2 and its mutants in cell models and xenografts.
- Analysis of glucose metabolic enzyme gene expression and pathway activity (glycolysis, pentose phosphate pathway).
Main Results:
- NSD2 (histone H3K36 methyltransferase) expression is elevated in tamoxifen-resistant breast cancer.
- NSD2 overexpression correlates with disease recurrence and poor survival.
- NSD2 drives endocrine resistance by methylating H3K36me2 at promoters of key metabolic enzymes, including HK2 and G6PD.
- NSD2 upregulates the pentose phosphate pathway (PPP), increasing NADPH and reducing reactive oxygen species (ROS) in resistant cells.
Conclusions:
- NSD2 epigenetically activates key glucose metabolic enzymes, contributing to tamoxifen resistance in breast cancer.
- NSD2 plays a crucial role in metabolic reprogramming associated with therapeutic resistance.
- NSD2 is a potential therapeutic target for overcoming endocrine resistance in breast cancer.
Related Concept Videos
Regulation of Metabolism
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Epigenetic Regulation
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Abnormal Proliferation

